Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL ER vs FLAGYL I.V. RTU IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.
Treatment of bacterial vaginosis (FDA-approved),Off-label: Clostridium difficile infection, anaerobic infections, trichomoniasis, amebiasis, giardiasis, rosacea, periodontal disease, Helicobacter pylori eradication
Treatment of anaerobic bacterial infections (intra-abdominal, skin and skin structure, gynecologic, bone and joint, central nervous system, lower respiratory tract, endocarditis),Treatment of trichomoniasis (symptomatic and asymptomatic),Treatment of bacterial vaginosis,Treatment of amebiasis (intestinal and hepatic),Prophylaxis of postoperative infection in contaminated or potentially contaminated colorectal surgery,Off-label: Management of Clostridium difficile infection, Helicobacter pylori eradication (part of combination therapy), Crohn's disease (perianal fistulas), rosacea (topical)
750 mg orally once daily for 10 days for bacterial vaginosis.
Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
8 hours (6-10 hours) in adults with normal renal function; prolonged to 12-24 hours in severe hepatic impairment.
Hepatic metabolism via side-chain oxidation and glucuronidation; metabolites are 5-nitroimidazoles and hydroxy metabolites; CYP450 enzymes (CYP2A6, CYP3A4, CYP2B6) partially involved.
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy-metronidazole (active) and acid metabolites. Enzymes: CYP450 (primarily CYP2A6 and CYP3A4).
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Renal (60-80% as unchanged drug and metabolites), fecal (6-15%), biliary (minor).
<20% (albumin).
<20%, primarily to albumin.
0.5-0.8 L/kg; indicates extensive tissue distribution including CNS.
0.8-1.2 L/kg; indicates extensive tissue penetration including CNS, bone, and abscesses.
Oral: 80-95% (extended-release formulation).
Oral: 100% (nearly complete absorption).
No adjustment necessary for GFR >10 m L/min; for GFR <10 m L/min, consider using immediate-release metronidazole instead of FLAGYL ER due to lack of data in severe renal impairment.
No adjustment required for GFR >10 m L/min. For GFR <10 m L/min: administer every 12 hours. Hemodialysis: administer normal dose after dialysis; no supplemental dose needed. Peritoneal dialysis: administer normal dose every 12 hours.
Child-Pugh Class A/B: no adjustment necessary. Child-Pugh Class C: reduce dose to 375 mg orally once daily (50% of usual dose).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 7.5 mg/kg every 12 hours). Child-Pugh C: use contraindicated or reduce dose to 7.5 mg/kg every 24 hours with close monitoring.
Safety and efficacy not established for FLAGYL ER in pediatric patients. Use immediate-release metronidazole for pediatric dosing.
Neonates (0-6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 12 hours. Infants/children (>6 weeks): 15 mg/kg IV loading, then 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.
No specific dose adjustment recommended based on age alone; use caution due to potential for decreased renal function and monitor for adverse effects.
No specific dose adjustment based solely on age. Monitor renal function and adjust if GFR <10 m L/min. Consider reduced hepatic clearance; use lowest effective dose and monitor for adverse effects.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Avoid chronic use. Reserved for anaerobic and protozoal infections.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Its use should be reserved for conditions described in the indications. Unnecessary use should be avoided.
Peripheral neuropathy (risk with prolonged use), CNS effects (seizures, encephalopathy), disulfiram-like reaction with alcohol, sodium overload (each tablet contains 84 mg sodium), hepatic impairment may increase risk of toxicity, renal impairment (dose adjustment not typically required but monitor), superinfection including C. difficile diarrhea.
Carcinogenicity risk (animal data; avoid unnecessary use),Seizures and peripheral neuropathy (discontinue if abnormal neurologic signs occur),Hepatic impairment: dose adjustment may be required; caution in severe liver disease,Renal impairment: accumulation of metabolites; monitor for toxicity,Blood dyscrasias: history of or current; monitor CBC with prolonged therapy,Candidiasis: may cause overgrowth; treat appropriately,Disulfiram-like reaction with alcohol: avoid alcohol during and for 48 hours after therapy,Drug interactions: warfarin (increased INR), lithium (increased toxicity), CYP450 inducers/inhibitors,Pregnancy: reserve for serious infections; use in trichomoniasis only if no alternative,Lactation: discontinue breastfeeding or drug, considering importance to mother
Hypersensitivity to metronidazole or other nitroimidazoles; concurrent use of disulfiram (psychotic reactions); caution in pregnancy (first trimester only if clearly needed; crosses placenta); breastfeeding (use caution due to potential carcinogenicity).
Hypersensitivity to metronidazole or other nitroimidazoles,First trimester of pregnancy (for trichomoniasis; relative contraindication),Concurrent use of disulfiram (psychotic reactions possible),Patients with Cockayne syndrome (risk of severe hepatic adverse reactions)
Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrups, cooking wine) during therapy and for 48 hours after last dose. No specific food restrictions otherwise.
No direct food interactions, but alcohol and alcohol-containing foods (e.g., sauces, vinegar, fermented products) must be strictly avoided during therapy and for 48 hours after completion due to risk of disulfiram-like reaction.
Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infections. Trimester 2 and 3: Use with caution; associated with increased risk of cleft lip/palate in some studies; avoid if possible.
Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: Generally considered safe for short-term treatment of bacterial vaginosis or trichomoniasis; no evidence of increased major malformations. However, use only if clearly needed.
Excreted in breast milk; M/P ratio ~0.9; American Academy of Pediatrics considers compatible with breastfeeding, but advise caution; monitor infant for diarrhea or oral thrush.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Infant serum levels may be up to 20% of maternal levels. Due to potential carcinogenicity in animal studies and concerns for infant gastrointestinal effects, the manufacturer recommends discontinuing breastfeeding during therapy and for 24-48 hours after last dose. Alternative washing and pumping may be considered.
No specific dose adjustments recommended based on pregnancy pharmacokinetics; however, due to increased GFR in pregnancy, consider monitoring therapeutic levels for severe infections.
Pregnancy may alter metronidazole pharmacokinetics: slightly increased clearance and volume of distribution. No specific dose adjustment is recommended; use standard dosing (e.g., 500 mg IV every 6-8 hours for anaerobic infections). Avoid high doses and prolonged therapy unless essential.
FLAGYL ER (metronidazole extended-release) is indicated for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy; discontinue if signs occur. Use with caution in hepatic impairment; dose adjustment may be needed. May cause metallic taste.
Flagyl IV RTU (metronidazole) is a nitroimidazole antibiotic used for anaerobic infections and protozoal diseases. Avoid alcohol during therapy and for 48 hours after due to disulfiram-like reaction. Infuse slowly over 30-60 minutes to minimize infusion reactions. Monitor for peripheral neuropathy and CNS effects with prolonged use. Use with caution in hepatic impairment; adjust dose in severe liver disease. May cause metallic taste. Do not mix with other drugs in the same IV line. Contraindicated in first trimester of pregnancy unless life-threatening.
Take this medication exactly as prescribed; do not crush or chew the extended-release tablets.,Avoid all alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Complete the full course even if symptoms improve to ensure infection is fully treated.,Report any numbness, tingling, or pain in hands or feet to your doctor immediately.,Inform your healthcare provider if you have liver disease, a history of blood disorders, or are pregnant or breastfeeding.
Do not drink alcohol or use products containing alcohol during treatment and for at least 48 hours after the last dose; this can cause severe nausea, vomiting, flushing, and headache.,This medication may cause a metallic taste in the mouth, which is temporary.,If you experience numbness, tingling, or pain in your hands or feet, or any signs of an allergic reaction, contact your healthcare provider immediately.,For IV administration, the infusion site should be monitored for signs of redness, swelling, or pain.,Take the medication exactly as prescribed; do not stop without consulting your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL ER vs FLAGYL I.V. RTU IN PLASTIC CONTAINER, answered by our medical review team.
FLAGYL ER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.. FLAGYL I.V. RTU IN PLASTIC CONTAINER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole, exerts bactericidal and antiprotozoal activity via reduction of its nitro group by bacterial or protozoal nitroreductases, forming toxic intermediates that disrupt DNA helical structure and inhibit nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL ER and FLAGYL I.V. RTU IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Nitroimidazole Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL ER is: 750 mg orally once daily for 10 days for bacterial vaginosis.. The standard adult dose of FLAGYL I.V. RTU IN PLASTIC CONTAINER is: Metronidazole: Initial loading dose of 15 mg/kg IV, followed by 7.5 mg/kg IV every 6 hours (max 4 g/day). For surgical prophylaxis: 15 mg/kg IV 1 hour before surgery.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL ER and FLAGYL I.V. RTU IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL ER is classified as Category C. Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infec. FLAGYL I.V. RTU IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. First trimester: Avoid use; data suggest possible teratogenic risk (cleft palate), though not conclusively. Second and third trimesters: General. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.